Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer
BackgroundFollicle-stimulating hormone (FSH) dysregulation plays a potential role in prostate cancer progression. The objective of this study was to evaluate whether higher FSH levels during androgen deprivation therapy (ADT) for recurrent prostate cancer could predict the development of castration-...
Saved in:
| Main Authors: | Kaleem Atchia, France-Hélène Joncas, Lily Summers Trasiewicz, Wei Phin Tan, Keyue Ding, Brant A. Inman, Paul Toren |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/view/171/101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01) -
Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01) -
Androgen Deprivation Therapy–Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients
by: Jie Lee, et al.
Published: (2025-06-01) -
Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01) -
Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)